Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • A strong welfare state mitigates the impact of the Great Recession

  • Costs to treat bleeding strokes increases 10 years later

  • For brain hemorrhage, risk of death lower at high-volume hospitals

  • Nursery places for three-year-olds: introduction of free entitlement did not deliver long-term benefits for children?s development, new research finds

  • Boosting use of multi-sensory environments in dementia care

  • Clot dissolver tpa's tardy twin could aid in stroke recovery

  • Exposure therapy appears helpful in treating patients with prolonged grief

  • Omega 3 can help children with ADD, experts say

  • Music therapy reduces depression in children, adolescents

  • Teens whose parents exert more psychological control have trouble with closeness, independence

  •